Fig. 6From: Anti-inflammatory protein TSG-6 secreted by bone marrow mesenchymal stem cells attenuates neuropathic pain by inhibiting the TLR2/MyD88/NF-κB signaling pathway in spinal microgliaIntrathecal administration of exogenous TSG-6 attenuates CCI-induced neuropathic pain and microglia activation. Dose-dependent reversal of mechanical allodynia (a) and thermal hyperalgesia (b) by intrathecal injection of TSG-6 at 7 days after CCI. c–e Dose-dependent inhibition of CCI-induced upregulation of IL-1β, IL-6, and TNF-α after intrathecal TSG-6 injection 3 h in the ipsilateral spinal cord dorsal horn at 7 days after the CCI surgery. The data are expressed as the means ± SD (n = 8 in each group). **P < 0.01 versus the CCI + PBS group. Statistical significance was determined by two-way analysis of variance (ANOVA) with post hoc Tukey test (a, b), one-way analysis of variance (ANOVA) with post hoc Tukey test (c–e)Back to article page